BofA/Merrill Lynch analyst Sumant Kulkarni reiterated a Buy rating and bumped his price target on Teva Pharma (NYSE: TEVA) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE